Hepatitis C Virus Infection and Vaccine Development.

Area of Science:

• Hepatology
• Virology
• Vaccinology

Background:

• Hepatitis C virus (HCV) establishes persistent infections, leading to chronic liver disease, cirrhosis, and hepatocellular carcinoma.
• Direct-acting antiviral (DAA) regimens achieve over 90% cure rates in developed nations, significantly advancing HCV eradication efforts.
• High treatment costs restrict DAA access in developing nations, where HCV burden is highest, and limited surveillance facilitates ongoing transmission.

Purpose of the Study:

• To review the development and progress of preventive and therapeutic vaccines against HCV.
• To contextualize vaccine development within the challenges of HCV biology, including drug resistance and transmission.

Main Methods:

• Review of scientific literature on HCV vaccine development.
• Analysis of various vaccine platforms including peptide, recombinant protein, HCV-like particle, DNA, and viral vector vaccines.

Main Results:

• Significant progress has been made in developing diverse vaccine candidates against HCV.
• Various platforms, including peptide, recombinant protein, HCV-like particle, DNA, and viral vector vaccines, are under investigation.

Conclusions:

• Despite advances in direct-acting antivirals, challenges in access and ongoing transmission necessitate the development of effective HCV vaccines.
• Further research into HCV biology is crucial for developing protective vaccines and addressing potential drug-resistant variants.